Jasper identifies path forward for briquilimab

Californian biotech Jasper Therapeutics (Nasdaq: JSPR) has announced that it will focus on the development of its lead product candidate, briquilimab, in chronic diseases and stem cell transplant for rare diseases.

This portfolio includes a new program on chronic urticaria, along with the company’s existing programs for lower-risk myelodysplastic syndrome (MDS), sickle cell disease, Fanconi anemia and severe combined immunodeficiency (SCID).

"Focusing on the most well-characterized opportunities with the clearest and potentially fastest pathway to market is in the best interest of patients and our shareholders"Jasper has prioritized rapidly starting a clinical trial in severe chronic urticaria because of pre-clinical and clinical studies showing inhibition of c-kit signaling, depletion of mast cells in skin and lung and extended pharmacokinetics of subcutaneous dosing.